Clinical Pharmacokinetics of Zidovudine: An Update

Clinical Pharmacokinetics

Volumn 30, Issue 4, 1996, Pages 251-262

  Acosta, Edward P ^a   Page, Linda M ^a   Fletcher, Courtney V ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; TISSUE DISTRIBUTION; ZIDOVUDINE;

EID: 0029968585     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630040-00001     Document Type: Review

References (56)

1. Fischl M, Richman D, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987; 317: 185-91
2. Fischl MA, Richman DD, Hansen N, et al. The safely and efficacy of zidovudine (AZT) in the treatment of mildly symptomatic human immunodeficiency virus type I (HIV) infection: a double-blind, placebo-controlled trial. Ann Intern Med 1990; 112: 727-37
3. Volberding PA, Lagakos SW, Koch MA, et al. Zidovudine in asymptomatic human immunodeficiency virus infection: a controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. N Engl J Med 1990; 322: 941-9
4. Volberding PA, Lagakos SW, Grimes JM, et al. The duration of zidovudine benefit in persons with asymptomatic HIV infection: prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA 1994; 272: 437-42
5. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
6. Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid concentrations of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987; 41: 407-12
7. Macnab KA, Gill MJ, Sutherland LR, et al. Erratic zidovudine bioavailability in HIV seropositive patients. J Antimicrob Chemother 1993; 31: 421-8
8. Ehrenpreis ED, Gulino SP, Patterson BK, et al. Kinetics of D-xylose absorption in patients with human immunodeficiency virus enteropathy. Clin Pharmacol Ther 1991; 49: 632-40
9. Fletcher CV, Rhame FS, Beatty CC, et al. Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease. Pharmacotherapy 1992; 12: 429-34
10. Blum MR, Liao SHT, Good SS, et al. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85 Suppl. 2a: 189-94
11. Bareggi S, Cinque P, Mazzei M, et al. Pharmacokinetics of zidovudine in HIV-positive patients with liver disease. J Clin Pharmacol 1994; 34: 782-6
12. Gitterman SR, Drusano GL, Egorin MJ, et al. Population pharmacokinetics of zidovudine. Clin Pharmacol Ther 1990; 48: 161-7
13. Luzier A, Morse GD. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res 1993; 21: 267-80
14. Tartaglione TA, Collier AC, Coombs RW, et al. Cerebrospinal fluid findings in patients before and during long-term oral zidovudine therapy. Arch Neurol 1991; 48: 695-9
15. Balis FM, Pizzo PA, Murphy RF, et al. The pharmacokinetics of zidovudine administered by continuous infusion in children. Ann Intern Med 1989; 110: 279-85
16. Henry K, Chinnock BJ, Quinn RP, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988; 259: 3023-6
17. Ruff A, Hamzeh F, Lietman P, et al. Excretion of zidovudine (ZDV) in human breast milk [abstract I11]. In: The 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7: Orlando, Florida
18. Sahai J, Gallicano K, Garber G, et al. Relationship between body weight, body surface area and serum zidovudine pharmacokinetic parameters in adult, male HIV-infected patients. AIDS 1994: 8; 793-6
19. Unadkat J, Tartaglione T, Opheim K, et al. Estimation of population pharmacokinetic parameters of zidovudine (ZDV or AZT) from AIDS patients enrolled in a phase II/III trial [abstract 3640]. In: Proceedings of the Fourth International Conference on AIDS; 1992 June 12-16: Stockholm, Sweden
20. Burger DM, Meenhorst PL, ten Napal CHH, et al. Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions. AIDS 1994; 8: 1683-9
21. Mentré F, Escolano S, Diquet B, et al. Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationships to long term efficacy and toxicity. Eur J Clin Pharmacol 1993; 45: 397-407
22. Fletcher CV, Balfour Jr HH. Variability in zidovudine serum concentrations. Pharmacotherapy 1996. In press
23. Noormohamed SE, Henry WK, Rhame FS, et al. Strategies for the control of zidovudine serum concentrations. Antimicrob Agents Chemother 1995; 39: 2792-7
24. Bawdon RE, Sobhi S, Dax JP. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am J Obstet Gynecol 1992; 167: 1570-4
25. Schenker S, Johnson RF, King TS, et al. Azidothymidine (zidovudine) transport by the human placenta. Am J Med Sci 1990; 299: 16-20
26. O'Sullivan MJ, Boyer PJJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Am J Obstet Gynecol 1993; 168: 1510-6
27. Good SS, Durack DT, deMiranda P. Biotransformation in various species and in humans of 3′-azido-3′-deoxythymidine, a potential agent for the treatment of AIDS [abstract 1690]. Fed Proc 1986; 45: 444
28. Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190-2
29. Dudley MN. Clinical pharmacokinetics of nucleoside antiretroviral agents. J Infect Dis 1995; 171 Suppl. 2: 99S-112S
30. Stagg MP, Cretton EM, Kidd L, et al. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51: 668-76
31. Cretton EM, Xie M, Bevan RJ, et al. Catabolism of 3′-azido-3′-deoxythymidine in hepatocytes and liver microsomes with evidence of formation of 3′-amino-3′-deoxythymidine, a highly toxic catabolite for human bone marrow cells. Mol Pharmacol 1990; 39: 258-66
32. Taburet AM, Naveau S, Zorza G, et al. Pharmacokinetics of zidovudine in patients with liver cirrhosis. Clin Pharmacol Ther 1990; 47: 731-9
33. Singlas E, Pioger JC, Taburet AM, et al. Zidovudine disposition in patients with severe renal impairment: influence of haemodialysis. Clin Pharmacol Ther 1989; 46: 190-7
34. Stretcher BN, Pesce AJ, Frame PT, et al. Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 1994; 38: 1541-7
35. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8: F1-5
36. Robbins BL, Rodman J, McDonald C, et al. Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cells. Antimicrob Agents Chemother 1994; 38: 115-21
37. Slusher JT, Kuwahara SK, Hamzeh FM, et al. Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedure. Antimicrob Agents Chemother 1992; 36: 2473-7
38. Unadkat JD, Collier AC, Crosby SS, et al. Pharmacokinetics of oral zidovudine (azidothymidine) in patients with AIDS when administered with and without a high-fat meal. AIDS 1990; 4: 229-32
39. Ruhnke M, Bauer FE, Seifert M, et al. Effects of standard breakfast on pharmacokinetics of oral zidovudine in patients with AIDS. Antimicrob Agents Chemother 1993; 37: 2153-8
40. Sahai J, Gallicano K, Garber G, et al. The effect of a protein meal on zidovudine pharmacokinetics in HIV-infected patients. Br J Clin Pharmacol 1992; 33: 657-60
41. Lotterer B, Ruhnke M, Trautmann M, et al. Decreased and variable systemic availability of zidovudine in patients with AIDS if administered with a meal. Eur J Clin Pharmacol 1991; 40: 305-8
42. Burger DM, Meenhorst PL, Koks CHW, et al. Pharmacokinetic interaction between rifampin and zidovudine. Antimicrob Agents Chemother 1993; 37: 1426-31
43. Narang PK, Sale M. Population based assessment of rifabutin effect on zidovudine disposition in AIDS patients [abstract]. Clin Pharmacol Ther 1993; 53: 219
44. Gallicano K, Sahai J, Swick L, et al. The effect of rifabutin (R) on zidovudine (Z) pharmacokinetics in HIV+ patients [abstract 486]. The 2nd National Conference on Human Retroviruses and Related Infections; 1995 Jan 29-Feb 2: Washington, DC
45. Lavrijsen KLM, Van Houdt JMG, Van Dyck DMJ, et al. Induction potential of fluconazole toward drug metabolizing enzymes in rats. Antimicrob Agents Chemother 1990; 34: 402-8
46. Sahai J, Gallicano K, Pakuts A, et al. Effect of fluconazole on zidovudine pharmacokinetics in patients infected with human immunodeficiency virus. J Infect Dis 1994; 169: 1103-7
47. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989; 46: 494-500
48. Weiner IM, Mudge GH. Renal tubular mechanisms for excretion of organic acids and bases. Am J Med 1964; 36: 743-62
49. Fletcher CV, Henry K, Noormohamed SE, et al. The pharmacologic effect of H2-antagonists with zidovudine. Pharmacotherapy 1995; 15: 701-8
50. Watts DH, Brown ZA, Tartaglione T, et al. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 1991; 163: 226-32
51. Balis FM, Pizzo PA, Eddy J, et al. Pharmacokinetics of zidovudine administered intravenously and orally in children with human immunodeficiency virus infection. J Pediatr 1989; 114: 880-4
52. Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr 1993; 122: 137-44
53. Sale M, Sheiner LB, Volberding P, et al. Zidovudine response relationships in early human immunodeficiency virus infection. Clin Pharmacol Ther 1993; 54: 556-66
54. Drusano GL, Balis FM, Gitterman SR, et al. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother 1994; 38: 1726-31
55. Fletcher CV, Acosta EP, Henry K, et al. Concentration-controlled zidovudine (ZDV) therapy: preliminary safety, virologic, and immunologic results [abstract 353]. In: The Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 29-Feb 2: Washington, DC
56. Hoetelmans RMW, Burger DM, Meenhorst PL, et al. Pharmacokinetic individualisation of zidovudine therapy: current state of pharmacokinetic-pharmacodynamic relationships. Clin Pharmacokinet 1996; 30 (4): 314-327